JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

化学療法による心筋症候群の患者の左心室排出分数の変化と心臓再同期療法の関連

  • 0Massachusetts General Hospital, Harvard Medical School, Boston.
Jama +

|

2019年11月13日

|

2019年11月13日

PubMedで要約を見る

まとめ

この要約は機械生成です。

心臓再同期療法 (CRT) は,化学療法による心筋不全の患者で心臓機能を改善しました. この研究では,CRTの埋め込み後に左心室排出分数 (LVEF) の有意な増加が示されました.

科学分野

  • 心臓腫瘍学
  • 心血管医学
  • 医療機器

背景

  • 化学療法による心筋病症 (CIC) は,不良の結果を伴う懸念が高まっています.
  • 早期発見と介入は,CICの管理に不可欠です.
  • 心臓再同期療法 (CRT) は,心不全の潜在的な治療法である.

研究 の 目的

  • CIC患者の心臓機能と臨床状態の改善におけるCRTの有効性を評価する.
  • 左心室排出分数 (LVEF) とCRT後の他の心臓のパラメータの変化を評価する.

主な方法

  • CIC患者30人を対象とした前向きな非対照的コホート研究.
  • 低 LVEF (≤35%),心不全症状 (NYHA クラスII- IV),および広 QRS複合体によるCRT移植を受けた患者.
  • 植入後6ヶ月間,追跡調査が行われました.

主要な成果

  • 平均LVEFの統計的に有意な改善は6ヶ月で28%から39% (10. 6%増加,P<. 001) に見られた.
  • 左心室の終末シストリック容量と終末ダイアストリック容量の有意な減少も認められた (P< 0. 001).
  • 肺胸炎,器官感染,心不全の入院など,有害事象はまれでした.

結論

  • 化学療法による心筋病症の患者で,CRTはLVEFの改善と正の関連性を示した.
  • これらの事前調査結果は,CRTがCICの管理に有効な選択肢である可能性を示唆しています.
  • これらの結果を確認するために,より大きなサンプルサイズと対照群でのさらなる研究が必要である.

関連する概念動画

Cardiomyopathy IV: Restrictive Cardiomyopathy 01:29

405

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy II: Dilated Cardiomyopathy 01:30

412

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care 01:29

287

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies 01:22

218

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy III: Hypertrophic Cardiomyopathy 01:29

329

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System 01:26

857

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...